Specific immunotherapy, which involves the administration of allergic extracts to patients with symptoms of allergic disorder, is the leading therapeutical tool of modern allergology. According to the latest studies immunotherapy not only reduces symptoms' severity but also may modify the course of allergic disease by reducing the risk of new sensitisations and development of more advanced stages of the disease.It has been hypothesized basing on clinical observation that perennial immunotherapy is more effective and safer in comparison to preseasonal immunotherapy. The aim of the study was to compare the effect of perennial and preseasonal immunotherapy on rhinoconjunctivitis symptoms and safety of both treatments.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
120
comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
Department of Internal diseases, Asthma and Allergy
Lodz, Poland
difference between preseasonal and perennial immunotherapy in area under curve of combined symptom medication score during 1st year of immunotherapy
combined symptom medication score was calculated as a sum of rhinoconjunctivitis symptoms and use of rescue medications during pollen season
Time frame: up to 3 months
difference between preseasonal and perennial immunotherapy in area under curve of combined symptom medication score during 2nd year of immunotherapy
combined symptom medication score was calculated as a sum of rhinoconjunctivitis symptoms and use of rescue medications during pollen season
Time frame: up to 3 months
difference between preseasonal and perennial immunotherapy in area under curve of combined symptom medication score during 3rd year of immunotherapy
combined symptom medication score was calculated as a sum of rhinoconjunctivitis symptoms and use of rescue medications during pollen season
Time frame: up to 3 months
frequency of adverse reactions during immunotherapy
Time frame: up to 3 years of immunotherapy
type of adverse reactions
Time frame: up to 3 years of immunotherapy
the differences from baseline in mean daily rhinoconjunctivitis symptoms score
Time frame: up to 3 months/4 years
the differences between study groups in mean daily rhinoconjunctivitis symptoms score
Time frame: up to 3 months/4 years
the differences from baseline in combined symptom medication score
Time frame: up to 3 months/4 years
the differences from baseline a in serum level of sIgG4
Time frame: the peak of each pollen season (June) during 4 years of study
the differences between study groups in combined symptom medication score
Time frame: up to 3 months/4 years
the differences between study groups in serum level of sIgG4
Time frame: up to 3 months/4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.